Trial Profile
A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Adenocarcinoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms EORTC protocol 1209-EnTF
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 21 Sep 2020 Status changed to discontinued due to slow accrual as per results presented at the 45th European Society for Medical Oncology Congress
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress